Deakin University
Browse

File(s) under permanent embargo

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

journal contribution
posted on 2005-11-16, 00:00 authored by X Zhan, L Martin, K Slobod, C Coleclough, T Lockey, S Brown, John StambasJohn Stambas, M Bonsignori, R Sealy, J Blanchard, J Hurwitz
A central obstacle to the design of a global HIV-1 vaccine is virus diversity. Pathogen diversity is not unique to HIV-1, and has been successfully conquered in other fields by the creation of vaccine cocktails. Here we describe the testing of an HIV-1 envelope cocktail vaccine. Six macaques received the vaccine, delivered by successive immunizations with recombinant DNA, recombinant vaccinia virus and recombinant envelope proteins. Following vaccination, animals developed a diversity of anti-envelope antibody binding and neutralizing activities toward proteins and viruses that were not represented by sequence in the vaccine. T-cells were also elicited, as measured by gamma-interferon production assays with envelope-derived peptide pools. Vaccinated and control animals were then challenged with the heterologous pathogenic SHIV, 89.6P. Vaccinated monkeys experienced significantly lower virus titers and better maintenance of CD4+ T-cells than unvaccinated controls. The B- and T-cell immune responses were far superior post-challenge in the vaccinated group. Four of six vaccinated animals and only one of six control animals survived a 44-week observation period post-challenge. The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives.

History

Journal

Vaccine

Volume

23

Issue

46-47

Pagination

5306 - 5320

Publisher

Elsevier Ltd.

Location

Guildford, England

ISSN

0264-410X

eISSN

1873-2518

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

Copyright 2005 Elsevier Ltd All rights reserved.